<- Go Home

Galderma Group AG

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services that span the spectrum of the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Dysport/Azzalure, Alluzience, Restylane, and Sculptra in injectable aesthetics; Cetaphil and Alastin in dermatological skincare; and Soolantra, Epiduo, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.

Market Cap

CHF 22.7B

Volume

478.9K

Cash and Equivalents

CHF 385.0M

EBITDA

CHF 841.9M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

CHF 3.0B

Profit Margin

69.54%

52 Week High

CHF 98.02

52 Week Low

CHF 68.63

Dividend

N/A

Price / Book Value

2.97

Price / Earnings

-38.2K

Price / Tangible Book Value

-9.58

Enterprise Value

CHF 25.2B

Enterprise Value / EBITDA

29.03

Operating Income

CHF 626.8M

Return on Equity

N/A

Return on Assets

N/A

Cash and Short Term Investments

CHF 385.0M

Debt

CHF 2.9B

Equity

CHF 7.6B

Revenue

CHF 4.3B

Unlevered FCF

N/A

Sector

Pharmaceuticals

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches